When Jimmie C. Holland, MD, conducts research, geriatric cancer patients are often her focus. Holland has studied telephone intervention as a way to monitor stress in patients aged 65 and older. She discussed the effort with OncologyLive.
Albert S. Baldwin, Jr, PhD, focuses on understanding the regulation and biological functions of NF-ÎºB and its role in disease, particularly in cancer, in a laboratory he heads at the UNC Lineberger Comprehensive Cancer Center.
Should an individual patient be denied the opportunity to potentially achieve the benefits from a therapeutic strategy because it is predicted that his or her tumor will have a relatively low chance to respond?
The translation of scientific advances in nanotechnology into cancer therapies, in vitro assays, and imaging tools is poised for takeoff, amid fresh excitement among investors and a mushrooming of findings from leading research institutions.
The complex regulation of NF-ÎºB activation has presented significant challenges for the development of anticancer agents, but researchers are now beginning to better understand and embrace this complexity to drive development of a variety of novel NF-ÎºB-targeting strategies.
Progression-free survival doubled in men with metastatic castration-resistant prostate cancer with no chemotherapy exposure who were treated with abiraterone acetate plus prednisone versus prednisone alone.